Harmony Biosciences Holdings, Inc. 8-K

What Happened

• On February 24, 2026, Harmony Biosciences Holdings, Inc. announced its financial results for the quarter and year ended December 31, 2025 via a press release (furnished as Exhibit 99.1 to the Form 8-K). The company also posted an investor presentation to its investor relations website and furnished it as Exhibit 99.2.

Key Details

• Date filed: February 24, 2026; reporting period: quarter and year ended December 31, 2025.
• Press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) were furnished with the 8-K; the presentation is available on the company’s investor relations site.
• The investor presentation may be used, in whole or part, in presentations to investors and contains forward-looking statements subject to the company’s risk disclosures (including risks noted in its 2024 Form 10-K filed Feb 25, 2025).
• The materials furnished with this 8-K are stated to be “furnished” (not “filed”) and thus have limited incorporation-by-reference and Section 18 liability.

Why It Matters

• This 8-K is the company’s official disclosure of its Q4 and full-year 2025 results and any accompanying commentary or outlook in the investor presentation. Retail investors should read the press release and investor presentation for revenue, earnings, cash flow, and management commentary to assess performance and near-term expectations.
• Note the presentation contains forward-looking statements and the company disclaims an obligation to update them except as required by law; review the company’s SEC filings (including the 2024 Form 10-K) for full risk context.